普米克令舒氧驱雾化吸入联合阿斯美及顺尔宁治疗咳嗽变异性哮喘疗（基础医学范文）.docVIP

普米克令舒氧驱雾化吸入联合阿斯美及顺尔宁治疗咳嗽变异性哮喘疗（基础医学范文） 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：普米克令舒氧驱雾化吸入联合阿斯美及顺尔宁治疗咳嗽变异性哮喘疗 1 1. 2 诊断标准与排除标准 4 2 结果 5 3 讨论 5 文2：普米克令舒雾化吸入治疗儿童咳嗽变异性哮喘的研究 8 1 资料与方法 9 1.1 一般资料 9 2 结果 9 3 讨论 10 参考文摘引言： 11 原创性声明（模板） 11 文章致谢（模板） 12 正文 普米克令舒氧驱雾化吸入联合阿斯美及顺尔宁治疗咳嗽变异性哮喘疗（基础医学范文） 文1：普米克令舒氧驱雾化吸入联合阿斯美及顺尔宁治疗咳嗽变异性哮喘疗 DOI：10.14163/j.cnki.11-5547.2018.08.049 Observation of efficacy of pulmicort oxygen-driven inhalation combined with Asmeton and Singulair in the treatment of cough variant asthma HE Xiao-zhu. Department of Respiratory Medicine， Jiangsu Kuhan Diahan Lake People.s Hospital， Kuhan 215345， China 【Abstract】 Objective To observe the clinical efficacy of budesonide suspeion for inhalation （Pulmicort） oxygen-driven inhalation combined with compound methoxyphenamine capsules （Asmeton） and montelukast sodium tablets （Singulair） in the treatment of cough variant asthma （CVA）. Methods A total of 64 cough variant asthma patients were randomly divided into observation group and control group， with 32 cases in each group. The control group was treated with bambuterol and loratadine， and the observation group was treated with Pulmicort， Asmeton and Singulair. The clinical effect in two group was observed. Results The observation group had higher total effective rate as 93.75% than 71.88% in the control group， and the difference was statistically significant （P0.05）. After treatment， the observation group had better forced expiratory volume in 1 second percentage of expected value （FEV1%）， forced vital capacity percentage of expected value （FVC%）， peak expiratory flow rates （PEFR） than before treatment， and the difference was statistically significant （P0.05）. After treatment， the observation group was better than the control group， and the difference was statistically significant （P0.05）. Conclusion Combination of pulmicort oxygen-driven inhalation， Asmeton and Singulair shows obvious efficacy in the treatment of cough variant asth